<i>This was pretty much free-market business</i><p>No, it wasn&#x27;t free-market at all. Much of Shkreli&#x27;s strategy relied on the barrier to entry created by FDA regulations. He priced the drug just low enough that it wouldn&#x27;t be worthwhile for another manufacturer to get approved.<p>Nothing free market here. It&#x27;s rent seeking, pure and simple.